Tests VC005 tablets against placebo in adults with active ankylosing spondylitis
Tests VC005 tablets in adults with active ankylosing spondylitis, a form of arthritis.
Plain-language title generated from the registry record
Registry title: Efficacy and Safety Phase III Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis.
Key facts
- Where
- Beijing, ChinaSee the site
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07172360, who can take part
Where in China
- Peking University People's HospitalBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Jiangsu vcare pharmaceutical technology co., LTD
- Trial code
- NCT07172360
- Record updated
- 2 January 2026
- Original description
This clinical trial is a multicenter, randomized, double-blind, controlled phase III clinical study.Read full original descriptionShow less
A Multicenter, Randomized, Double-blind, Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of VC005 Tablets in Subjects With Active Ankylosing Spondylitis
This clinical trial is a multicenter, randomized, double-blind, controlled phase III clinical study.
Inclusion: The subject understands and voluntarily signs the informed consent form (ICF) and is willing and able to comply with the study protocol; The subject is between 18 and 70 years of age (including borderline values) at the time of signing the ICF, regardless of gender; The subject has been diagnosed with AS according to the 1984 New York Revised Criteria for Ankylosing Spondylitis.
Exclusion: Individuals who have undergone organ transplantation in the past and require continuous use of immunosuppressants; Those who may be allergic to VC005, similar drugs or their excipients; Those who, for any reason, are considered by the investigator to be unsuitable for participation in this study.